Suppr超能文献

二氢叶酸还原酶是人类病原体抗真菌药物研发的有效靶点。

Dihydrofolate Reductase Is a Valid Target for Antifungal Development in the Human Pathogen .

机构信息

Department of Molecular Immunology and Biochemistry, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.

National Program in Biotechnology, Ministry of Science, Technology and Innovation, Bogota, Colombia.

出版信息

mSphere. 2020 Jun 24;5(3):e00374-20. doi: 10.1128/mSphere.00374-20.

Abstract

While the folate biosynthetic pathway has provided a rich source of antibacterial, antiprotozoal, and anticancer therapies, it has not yet been exploited to develop uniquely antifungal agents. Although there have been attempts to develop fungal-specific inhibitors of dihydrofolate reductase (DHFR), the protein itself has not been unequivocally validated as essential for fungal growth or virulence. The purpose of this study was to establish dihydrofolate reductase as a valid antifungal target. Using a strain with doxycycline-repressible transcription of ( strain), we were able to demonstrate that Dfr1p is essential for growth Furthermore, nutritional supplements of most forms of folate are not sufficient to restore growth when Dfr1p expression is suppressed or when its activity is directly inhibited by methotrexate, indicating that has a limited capacity to acquire or utilize exogenous sources of folate. Finally, the strain was rendered avirulent in a mouse model of disseminated candidiasis upon doxycycline treatment. Collectively, these results confirm the validity of targeting dihydrofolate reductase and, by inference, other enzymes in the folate biosynthetic pathway as a strategy to devise new and efficacious therapies to combat life-threatening invasive fungal infections. The folate biosynthetic pathway is a promising and understudied source for novel antifungals. Even dihydrofolate reductase (DHFR), a well-characterized and historically important drug target, has not been conclusively validated as an antifungal target. Here, we demonstrate that repression of DHFR inhibits growth of , a major human fungal pathogen. Methotrexate, an antifolate, also inhibits growth but through pH-dependent activity. In addition, we show that has a limited ability to take up or utilize exogenous folates as only the addition of high concentrations of folinic acid restored growth in the presence of methotrexate. Finally, we show that repression of DHFR in a mouse model of infection was sufficient to eliminate host mortality. Our work conclusively establishes DHFR as a valid antifungal target in .

摘要

虽然叶酸生物合成途径为开发抗菌、抗寄生虫和抗癌疗法提供了丰富的资源,但尚未将其用于开发独特的抗真菌药物。尽管已经尝试开发真菌特异性二氢叶酸还原酶 (DHFR) 抑制剂,但该蛋白本身尚未明确验证为真菌生长或毒力所必需。本研究旨在将二氢叶酸还原酶确立为有效的抗真菌靶标。使用四环素可诱导转录的菌株 ( 株),我们能够证明 Dfr1p 对于生长是必需的。此外,当 Dfr1p 的表达受到抑制或其活性被甲氨蝶呤直接抑制时,大多数形式的叶酸的营养补充剂不足以恢复生长,这表明 具有有限的能力来获取或利用外源性叶酸来源。最后,在给予多西环素治疗的播散性念珠菌病小鼠模型中, 株变得无致病性。总之,这些结果证实了靶向二氢叶酸还原酶的有效性,并且可以推断,叶酸生物合成途径中的其他酶作为设计新的有效疗法来对抗危及生命的侵袭性真菌感染的策略也是有效的。叶酸生物合成途径是开发新型抗真菌药物的一个有前途且研究不足的来源。即使是二氢叶酸还原酶 (DHFR),一种具有良好特征且具有重要历史意义的药物靶点,也尚未被明确验证为抗真菌靶点。在这里,我们证明了 DHFR 的抑制会抑制主要的人类真菌病原体的生长。甲氨蝶呤,一种抗叶酸药物,也抑制生长,但通过 pH 依赖性活性。此外,我们表明 具有有限的摄取或利用外源性叶酸的能力,只有添加高浓度的叶酸才能在甲氨蝶呤存在下恢复生长。最后,我们表明在感染小鼠模型中抑制 DHFR 足以消除宿主死亡率。我们的工作最终确立了 DHFR 作为 中的有效抗真菌靶标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb42/7316490/c46de7779dd1/mSphere.00374-20-f0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验